Trusted access to every medicine, every market.
Comparator sourcing, named-patient supply, clinical-trials logistics and contract manufacturing — delivered worldwide under WHO GDP-certified cold-chain conditions.
Services
Built for sponsors, hospitals and procurement teams
Seven integrated services that solve sourcing, regulatory and logistics problems for clinical and commercial pharma supply.

Comparator sourcing
Reference-listed drug and active comparator supply for clinical trials across global markets.

Clinical trials supply
End-to-end IMP sourcing, kitting and depot-to-site logistics for sponsors and CROs.

Named patient supply
Compliant supply of unlicensed or hard-to-find medicines for individual patients.

Contract manufacturing
Toll and contract manufacturing partnerships with vetted, regulator-approved facilities.

Dossiers & stability
Regulatory dossiers, stability programs and lifecycle documentation support.

Validated cold-chain
Qualified shipping lanes, validated containers and continuous temperature monitoring.

Competitive pricing
Direct-from-manufacturer pricing with transparent cost build-ups and forecasting.
Catalog
Featured products across regulator-approved registers
Recently updated items across the regional drug registers we serve worldwide.

Anzupgo 20 mg
Delgocitinib · 20 MG

Zoryve 0.15 %
Roflumilast · 0.15 %

Solufy 1 mg
Aripiprazole · 1 MG

Zoryve 0.3 %
Roflumilast · 0.3 %

Opzelura 1.5 %
Ruxolitinib (Ruxolitinib Phosphate) · 1.5 %

Awiqli 1050 Unit
Insulin Icodec · 1050 UNIT

Zoryve 0.3 %
Roflumilast · 0.3 %

Ubrelvy 50 mg
Ubrogepant · 50 MG
Worldwide reach
We source and supply worldwide
Our online catalog is searchable by two regulator-approved registers — USA (NDC) and Europe (EMA) — but our sourcing and named-patient supply reach far beyond them: from 60+ countries to wherever you need delivery.
Talk to sourcing
Need a specific molecule, brand or batch?
Share your protocol, target market and timelines. Our sourcing team responds within one business day with availability, lead time and indicative pricing.